Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Hematopoietic Stem Cell Function and Differentiation Is Regulated By DCAF7 through Polycomb Repressive Complex 1 (PRC1) Modulation

Johanna Melo-Cardenas, Lavanya Bezavada, Te Ling, Amber Broadhurst, Anitria Cotton, Jeremy Chase Crawford, Amanda Nourse, Vishwajeeth Pagala, Qiong Zhang, Wojciech Rosikiewicz, Hongjian Jin, Dirk Loeffler, John D. Crispino

Blood (2024) 144 (Supplement 1): 1272.

https://doi.org/10.1182/blood-2024-210287

Published: 2024

Journal Articles

Regulation of Alternative Splicing in B-Cell ALL By DYRK1A

Qi Jin, Ethan Harris, Jacquelyn A. Myers, Anitria Cotton, Jeremy Wen, Johanna Melo-Cardenas, Akihide Yoshimi, Omar Abdel-Wahab, Esther A. Obeng, John D. Crispino

Blood (2023) 142 (Supplement 1): 39.

https://doi.org/10.1182/blood-2023-174923

Published: 2023

Journal Articles

CALR goes rogue

Johanna Melo-Cardenas, John D. Crispino

Blood (2023) 141 (8): 818–820.

https://doi.org/10.1182/blood.2022018788

Published: 2023

Journal Articles

IL-13/IL-4 signaling contributes to fibrotic progression of the myeloproliferative neoplasms

Johanna Melo-Cardenas, Lavanya Bezavada, Jeremy Chase Crawford, Sandeep Gurbuxani, Anitria Cotton, Guolian Kang, Jeffrey Gossett, Christian Marinaccio, Rona Weinberg, Ronald Hoffman, Anna Rita Migliaccio, Yan Zheng, Marta Derecka, Ciro R. Rinaldi, John D. Crispino

Blood (2022) 140 (26): 2805–2817.

https://doi.org/10.1182/blood.2022017326

Published: 2022

Includes: Supplemental data

Journal Articles

DDB1 and CUL4 Associated Factor 7 (DCAF7) Is Essential for Hematopoiesis

Johanna Melo-Cardenas, Lavanya Bezavada, Anitria Cotton, John D. Crispino

Blood (2022) 140 (Supplement 1): 8586–8587.

https://doi.org/10.1182/blood-2022-158098

Published: 2022

Journal Articles

IL13 Contributes to Fibrotic Progression of the Myeloproliferative Neoplasms

Johanna Melo-Cardenas, Lavanya Bezavada, Jeremy Chase Crawford, Sandeep Gurbuxani, Anitria Cotton, Christian Marinaccio, John D. Crispino

Blood (2021) 138 (Supplement 1): 60.

https://doi.org/10.1182/blood-2021-151492

Published: 2021

Journal Articles

USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism

Johanna Melo-Cardenas, Yuanming Xu, Juncheng Wei, Can Tan, Sinyi Kong, Beixue Gao, Elena Montauti, Gina Kirsammer, Jonathan D. Licht, Jindan Yu, Peng Ji, John D. Crispino, Deyu Fang

Blood (2018) 132 (4): 423–434.

https://doi.org/10.1182/blood-2017-10-811760

Published: 2018

Includes: Supplemental data

Journal Articles

The Deubiquitylase Usp22 Is Important for KRAS-Driven Myeloproliferative Disease

Johanna Melo-Cardenas, Yuanming Xu, Beixue Gao, Deyu Fang

Blood (2015) 126 (23): 1250.

https://doi.org/10.1182/blood.V126.23.1250.1250

Published: 2015

Journal Articles

BMS-936564 (MDX1338): A Fully Human Anti-CXCR4 Antibody Induces Apoptosis in an in Vitro Model of Stromal – Leukemia Cell Interaction for Chronic Lymphocytic Leukemia.

Manoj Kumar Kashyap, PhD, Deepak Kumar, PhD, Harrison Jones Jones, BS, Michael Y. Choi, MD, Johanna Melo-Cardenas, B.Sc, Michelle R. Kuhne, PhD, Peter Sabbatini, PhD, Lewis Cohen, MD, MS, Suresh Shelat, MD-PhD, Pina M Cardarelli, Ph.D., Thomas J. Kipps, MD, PhD, Januario E. Castro, M.D.

Blood (2012) 120 (21): 2887.

https://doi.org/10.1182/blood.V120.21.2887.2887

Published: 2012

Journal Articles

Heat Shock Protein 90 (Hsp90) Activity Status Is An Independent Prognostic Marker in Chronic Lymphocytic Leukemia (CLL) and Correlates with IgV H Mutational Status, ZAP-70 Expression and Time to First Treatment

Januario E. Castro, M.D., Juan S. Barajas-Gamboa, M.D., Julio A. Diaz-Perez, M.D., M.S., Lina M. Ariza-Serrano, M.D. (c), Johanna Melo-Cardenas, B.Sc, Mauricio Rodriguez, D.D.S., M.S., Mauricio Urquiza, Ph.D., Thomas J. Kipps, M.D., Ph.D

Blood (2011) 118 (21): 2544.

https://doi.org/10.1182/blood.V118.21.2544.2544

Published: 2011

Journal Articles

Ad-ISF35-Transduced Autologous Cells In Combination with Fludarabine, Cyclophosphamide, Rituximab (FCR) Induces Complete and Partial Responses In a Phase 1b Study for Patients with Fludarabine-Refractory and/or Del(17p)/p53-Defective Chronic Lymphocytic Leukemia (CLL)

Januario E. Castro, M.D., Lee Schwartzberg, MD, FACP, Javier Pinilla-Ibarz, MD, PhD, Johanna Melo-Cardenas, B.Sc, Juan S. Barajas-Gamboa, M.D., Mark J. Cantwell, PhD, Thomas J. Kipps, M.D., Ph.D

Blood (2011) 118 (21): 168.

https://doi.org/10.1182/blood.V118.21.168.168

Published: 2011

Journal Articles

Agelastatin A (AgA), a Marine Sponge Derived Alkaloid, Inhibits Wnt/Beta-Catenin Signaling and Selectively Induces Apoptosis in Chronic Lymphocytic Leukemia Independently of p53

Michael Y. Choi, MD, Johanna Melo Cardenas, BSc, Desheng Lu, MD, PhD, Jian Yu, PhD, E. Paige Stout, PhD, Raymond P. Wu, Ph.D., John M Horton, B.S., Allison Gomez, Julio A. Diaz-Perez, M.D., M.S., Dennis A. Carson, M.D., Tadeusz F. Molinski, PhD, Thomas J. Kipps, M.D., Ph.D, Januario E. Castro, M.D.

Blood (2011) 118 (21): 1786.

https://doi.org/10.1182/blood.V118.21.1786.1786

Published: 2011

Journal Articles

Ad-ISF35 Intratumoral Administration Induces a Bystander Effect and Immune-Mediated Tumor Rejection with a Safe Vector Biodistribution and Toxicology Profile In a NHL Mouse Model.

Johanna Melo-Cardenas, B.Sc, Mauricio Urquiza, PhD, Robier Aguillon-Prada, M.D, Thomas J. Kipps, MD, PhD, Januario E Castro, M.D

Blood (2010) 116 (21): 1470.

https://doi.org/10.1182/blood.V116.21.1470.1470

Published: 2010

Journal Articles

Ad-ISF35- Transduced Autologous Cells Promote In Vitro and In Vivo Chemosensitization to FCR and Durable Complete Responses In Patients with Del(17p)/P53 Defective Chronic Lymphocytic Leukemia.

Januario E Castro, M.D, Johanna Melo-Cardenas, B.Sc, Juan Sebastian Barajas-Gamboa, M.D, Mauricio Urquiza, PhD, Mark J. Cantwell, PhD, Thomas J. Kipps, MD, PhD

Blood (2010) 116 (21): 1472.

https://doi.org/10.1182/blood.V116.21.1472.1472

Published: 2010

Journal Articles

Immune Gene Therapy for Patients with CLL Using Repeat Dose Intranodal Injection of Ad-ISF35, a Replication Incompetent Vector Expressing a Membrane-Stable CD40 Binding Protein.

Januario E Castro, M.D, Johanna Melo-Cardenas, B.Sc, Juan Sebastian Barajas-Gamboa, M.D, Ramin Sean Pakbaz, M.D, Mauricio Urquiza, PhD, Thomas J. Kipps, MD, PhD

Blood (2010) 116 (21): 1476.

https://doi.org/10.1182/blood.V116.21.1476.1476

Published: 2010

Journal Articles

Ofatumumab and High-Dose Methylprednisolone Is An Effective Salvage Treatment for Heavily Pretreated, Unfit or Refractory Patients with Chronic Lymphocytic Leukemia: Single Institution Experience

Januario E Castro, M.D, Juan Sebastian Barajas-Gamboa, M.D, Johanna Melo-Cardenas, B.Sc, Rosa N Paz, Cesar Bernal-Corzo, Amine Ale-Ali, Pharm., D., Danelle F. James, M.D, Thomas J. Kipps, MD, PhD

Blood (2010) 116 (21): 4638.

https://doi.org/10.1182/blood.V116.21.4638.4638

Published: 2010

Journal Articles

Ad-ISF35-Transduced Autologous Cells Promote in Vitro and In Vivo Chemosensitization to FCR in Patients with Del(17p) / P53 Defective Chronic Lymphocytic Leukemia.

Januario E. Castro, M.D., Johanna Melo-Cardenas, B.Sc, Jose Sandoval-Sus, Mauricio Urquiza, Charles Prussak, PhD, Thomas J. Kipps, MD, PhD

Blood (2009) 114 (22): 376.

https://doi.org/10.1182/blood.V114.22.376.376

Published: 2009

Journal Articles

A Phase I Study of Immune Gene Therapy for Patients with CLL Using Intranodal Injection of ISF35, a Membrane-Stable CD40 Binding Protein.

Januario Castro, MD, Jose D. Sandoval, MD, Johanna Melo-Cardenas, B.Sc, Denise Darrah, RN, Mauricio Urquiza, PhD, Charles Prussak, PhD, Thomas J. Kipps, MD, PhD

Blood (2008) 112 (11): 2100.

https://doi.org/10.1182/blood.V112.11.2100.2100

Published: 2008

NARROW

Hematopoietic Stem Cell Function and Differentiation Is Regulated By DCAF7 through Polycomb Repressive Complex 1 (PRC1) Modulation

Regulation of Alternative Splicing in B-Cell ALL By DYRK1A

CALR goes rogue

IL-13/IL-4 signaling contributes to fibrotic progression of the myeloproliferative neoplasms

DDB1 and CUL4 Associated Factor 7 (DCAF7) Is Essential for Hematopoiesis

IL13 Contributes to Fibrotic Progression of the Myeloproliferative Neoplasms

USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism

The Deubiquitylase Usp22 Is Important for KRAS-Driven Myeloproliferative Disease

BMS-936564 (MDX1338): A Fully Human Anti-CXCR4 Antibody Induces Apoptosis in an in Vitro Model of Stromal – Leukemia Cell Interaction for Chronic Lymphocytic Leukemia.

Heat Shock Protein 90 (Hsp90) Activity Status Is An Independent Prognostic Marker in Chronic Lymphocytic Leukemia (CLL) and Correlates with IgV H Mutational Status, ZAP-70 Expression and Time to First Treatment

Ad-ISF35-Transduced Autologous Cells In Combination with Fludarabine, Cyclophosphamide, Rituximab (FCR) Induces Complete and Partial Responses In a Phase 1b Study for Patients with Fludarabine-Refractory and/or Del(17p)/p53-Defective Chronic Lymphocytic Leukemia (CLL)

Agelastatin A (AgA), a Marine Sponge Derived Alkaloid, Inhibits Wnt/Beta-Catenin Signaling and Selectively Induces Apoptosis in Chronic Lymphocytic Leukemia Independently of p53

Ad-ISF35 Intratumoral Administration Induces a Bystander Effect and Immune-Mediated Tumor Rejection with a Safe Vector Biodistribution and Toxicology Profile In a NHL Mouse Model.

Ad-ISF35- Transduced Autologous Cells Promote In Vitro and In Vivo Chemosensitization to FCR and Durable Complete Responses In Patients with Del(17p)/P53 Defective Chronic Lymphocytic Leukemia.

Immune Gene Therapy for Patients with CLL Using Repeat Dose Intranodal Injection of Ad-ISF35, a Replication Incompetent Vector Expressing a Membrane-Stable CD40 Binding Protein.

Ofatumumab and High-Dose Methylprednisolone Is An Effective Salvage Treatment for Heavily Pretreated, Unfit or Refractory Patients with Chronic Lymphocytic Leukemia: Single Institution Experience

Ad-ISF35-Transduced Autologous Cells Promote in Vitro and In Vivo Chemosensitization to FCR in Patients with Del(17p) / P53 Defective Chronic Lymphocytic Leukemia.

A Phase I Study of Immune Gene Therapy for Patients with CLL Using Intranodal Injection of ISF35, a Membrane-Stable CD40 Binding Protein.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only